Skip to content
Search

Latest Stories

Ex-Haleon VP Bas Vorsteveld joins Kenvue

Kenvue appoints Bas Vorsteveld as area managing director for Northern Europe
Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

Bas Vorsteveld announced his departure from Haleon in October 2024, after “a journey of nearly 19 amazing years”

Bas Vorsteveld, former Haleon’s vice-president and general manager for Great Britain and Ireland (GBI), has been appointed as Kenvue's new area managing director for Northern Europe.

In his new role, he will oversee the company’s operations across the UK, Ireland, Norway, Sweden, Denmark, and Finland, managing a portfolio of iconic brands, including Nicorette, Aveeno, Johnson’s Baby, Listerine, Neutrogena, Calpol, OGX, and Imodium.


Vorsteveld has over 30 years of experience in consumer goods and healthcare.

At Haleon, he played a pivotal role in driving its GBI business following its separation from GSK, delivering significant growth and earning notable recognition, including Best Company at the UK Pharmacy Awards 2024.

He announced his departure from Haleon in October 2024, after “a journey of nearly 19 amazing years.”

Until recently, Vorsteveld was president of the board of the PAGB, spearheading the organisation’s five-year strategy focused on advancing self-care to help alleviate healthcare pressures.

He has held several roles across Europe with GSK Consumer Healthcare including VP & Head of Commercial Excellence EMEA, VP & General Manager France and French speaking Africa & Maghreb, and GM Benelux. Prior to that, he held GM roles at Novartis. He started his career at Campina.

Expressing his enthusiasm for the new role, Vorsteveld said: “Kenvue’s iconic brands speak for themselves, and I am excited by the truly holistic approach to self-care we can offer through the entire range of different categories we thrive in.

“I’m thrilled to join the Northern Europe team, and I look forward to getting out across the region to spend time with our customers and stakeholders across the industry as well as our dedicated team.”

Welcoming Bas to the leadership team, Carlton Lawson, group president, Europe, Middle East, Africa and Latin America at Kenvue, said: “With almost three decades of experience in consumer goods and healthcare, Bas brings a proven track record of delivering industry leading growth, building high performing teams and deep industry knowledge that will be invaluable as we work to further boost Kenvue’s regional performance and growth.

“I’m confident that his experience advocating for the role our industry can and should play in promoting the value of self-care will help us deliver on our clear purpose to put the power of everyday care into the hands of more consumers.”

More For You

Youth vaping : project to examine health impacts on children

Youth vaping : project to examine health impacts on children

Youth vaping: £62M research project to examine health impacts on children

The UK government has announced a £62 million research project to investigate the long-term health effects of vaping on young people, alongside wider influences on adolescent health and wellbeing.

While vaping is considered less harmful than smoking and can aid adult smokers in quitting, youth vaping has skyrocketed in recent years, with a quarter of 11 to 15-year-olds having tried it, the Department of Health and Social Care (DHSC) noted in a release.

Keep ReadingShow less
David Thomas Steps In as NPA’s New Wales Representative
Five NPA members are contesting for the remaining position in England (gettyimages)

NPA board update: David Thomas succeeds Raj Aggarwal OBE

Five NPA members are contesting for the remaining position in England

David Thomas, owner of LT Chemists in Newport, will replace Raj Aggarwal OBE as the next National Pharmacy Association (NPA) board member for Wales, following an uncontested election this month.

Following the conclusion of a nomination process last week, Baldev Bange, Aisling O’Brien, Sehar Shahid, and Sanjay Ganvir have been re-elected to the Board, representing areas of England and Scotland, according to a statement from NPA.

Keep ReadingShow less
Public Policy Projects calls for better use of community pharmacy skill mix to improve medicines adherence
Non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed. (gettyimages)

Leverage pharmacy skill mix to improve medicines adherence - report suggests

The report also suggested expanding the community pharmacy contractual framework to enable community pharmacy to deliver medicines reviews

Pharmacy technicians and assistants should be enabled to talk to patients about their medications to improve medicines adherence, a new report has recommended.

The report, How medicines optimisation contributes to population health, published recently by policy institute Public Policy Projects, highlighted that non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed.

Keep ReadingShow less
GHP calls for 10% mandated protected learning time for NHS pharmacists in new campaign
Many pharmacists end up doing ‘unpaid work’ to catch up with the required training (gettyimages)

Increase protected learning time for NHS pharmacists – GHP launches national campaign

Many pharmacists end up doing ‘unpaid work’ to catch up with the required training or completing self-learning in their own time.

The Guild of Healthcare Pharmacists (GHP) has launched a national campaign advocating for pharmacists working in the NHS to have a minimum of 10% of their contracted hours protected for supporting professional activities (SPA).

In a statement published on 7 February 2025, the GHP emphasised that this protected time “should be recognized by employers and embedded in job plans.”

Keep ReadingShow less
Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Kinnock confirms that an announcement on the 2025/26 GP contract would be made before April 2025

The 2025/26 pharmacy contract consultation will include a review of the medicine margin and reimbursement arrangements, health and care minister Stephen Kinnock has confirmed.

Kinnock made this statement in response to a written question from Nick Timothy, Conservative MP for West Suffolk, who asked the secretary of state for health and social care, if he will review the reimbursement system for pharmacies and GP practices dispensing medicines.

Keep ReadingShow less